It targets three hormone receptors at once, GLP-1, GIP, and glucagon, and the early trial data on weight loss is striking
As a fellowship-trained, board-certified Pediatric Obesity Medicine specialist, my goal is to help parents understand what this means and how to access these safe, proven, and expertly guided treatments for their child
Our kefirs natural protein is another benefit not to miss since it supports energy levels, healthy blood sugars, muscle health, and satisfaction at meals when paired with fiber-rich foods like the fruit used here
widely used off-label for significant weight loss Average weight loss: Up to 21% Notable facts: Dual-actiontargets both GLP-1 and GIP hormones for enhanced effectiveness Zepbound (tirzepatide) Approved for: Chronic weight management Released in: November 2023 Common use today: FDA-approved specifically for obesity Average weight loss: Up to 22% Notable facts: One of the most effective medications currently available for weight loss Saxenda (liraglutide 3 mg) Approved for: Weight management in adults and adolescents (12+) Released in: December 2014 Common use today: An older GLP-1 medication option for obesity Average weight loss: About 58% Notable facts: Requires daily injections, unlike newer weekly alternatives Rybelsus (oral semaglutide) Approved for: Type 2 diabetes Released in: September 2019 Common use today: The only oral GLP-1 medication currently available Average weight loss: Approximately 510%, depending on dosage Notable facts: Ideal for those uncomfortable with injections CagriSema (cagrilintide + semaglutide) Status: Currently in Phase III trials (not yet FDA-approved) Average weight loss: Up to 20% in clinical trials Notable facts: Combines GLP-1 agonist semaglutide with amylin receptor agonist cagrilintide for enhanced weight-loss results Orforglipron (oral GLP-1) Status: FDA submission expected by late 2025 Average weight loss: Around 8% (approximately 16 pounds) in clinical studies Notable facts: Small-molecule oral GLP-1 agonist
